CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro

Blood

Volumn 103, Issue 6, 2004, Pages 2162-2169

  Rothenfusser, Simon ^b   Hornung, Veit ^b   Ayyoub, Maha ^b   Britsch, Stefanie ^b   Towarowski, Andreas ^b   Krug, Anne ^b   Sarris, Anja ^b   Lubenow, Norbert ^b   Speiser, Daniel ^b   Endres, Stefan ^b   Hartmann, Gunther ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD8 ANTIGEN; CPG A OLIGONUCLEOTIDE; CPG B OLIGONUCLEOTIDE; GRANZYME B; MELAN A; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; MEMORY CELL; PLASMA CELL; PRIORITY JOURNAL;

EID: 12144290582     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1091     Document Type: Article

References (53)

1. Freund J, McDermott K. Sensitization to horse serum by means of adjuvants. Proc Soc Exp Biol Med. 1942;49:548-553.
2. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
3. Bendelac A, Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med. 2002;195:F19-F23.
4. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
5. Verthelyi D, Kenney RT, Seder RA, et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol. 2002;168:1659-1663.
6. Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol. 2002;168:1212-1218.
7. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol. 2000;164:2372-2378.
8. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol. 2000;165:539-547.
9. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. 2002;169:3892-3899.
10. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol. 2002;32:3235-3245.
11. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944-953.
12. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164:1617-1624.
13. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237-9242.
14. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of TLR1-10 mRNA in cellular subsets of human PBMC and sensitivity to CpG ODN. J Immunol. 2002;168:4531-4537.
15. Stacey KJ, Sester DP, Sweet MJ, Hume DA. Macrophage activation by immunostimulatory DNA. Curr Top Microbiol Immunol. 2000;247:41-58.
16. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28:2045-2054.
17. Hacker H, Vabulas RM, Takeuchi O, et al. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med. 2000;192:595-600.
18. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31:2154-2163.
19. Rothenfusser S, Tuma E, Endres S, Hartmann G. Plasmacytoid dendritic cells: the key to CpG(1). Hum Immunol. 2002;63;1111-1119.
20. Verthelyi D, Ishii K, Gursel M, Takeshita F, Klinman D. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001;166:2372-2377.
21. Rothenfusser S, Hornung V, Krug A, et al. Distinct CpG oligonucleoticle sequences activate human gamma delta T cells via interferon-alpha/beta. Eur J Immunol. 2001;31:3525-3534.
22. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157:1840-1845.
23. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
24. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
25. Fisch P, Meuer E, Pende D, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human V-γ/9/Vδ2 T cells in tumor immunity. Eur J Immunol. 1997;27:3368-3379.
26. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190:705-715.
27. Zippelius A, Pittet MJ, Batard P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med. 2002;195:485-494.
28. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31:3026-3037.
29. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
30. Jager E, Hohn H, Necker A, et al. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer. 2002;98:376-388.
31. Azuma M, Phillips JH, Lanier LL. CD28 T lymphocytes: antigenic and functional properties. J Immunol. 1993;150:1147-1159.
32. Cocks BG, Chang CC, Carballido JM, et al. A novel receptor involved in T-cell activation. Nature. 1995;376:260-263.
33. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000;164:1148-1152.
34. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
35. Biron CA. Interferons alpha and beta as immune regulators-a new look. Immunity. 2001;14:661-664.
36. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002;188:81-96.
37. Ronchese F, Hausmann B. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J Exp Med. 1993;177:679-690.
38. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156-1159.
39. Epstein MM, Di Rosa F, Jankovic D, Sher A, Matzinger P. Successful T cell priming in B cell-deficient mice. J Exp Med. 1995;182:915-922.
40. Monach PA, Schreiber H, Rowley DA. CD4+ and B lymphocytes in transplantation immunity, II: augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 1993;55:1356-1361.
41. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
42. Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol. 2001;1:177-186.
43. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998;188:2335-2342.
44. Sun S, Zhang X, Tough D, Sprent J. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. Springer Semin Immunopathol. 2000;22:77-84.
45. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996;272:1947-1950.
46. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999;189:521-530.
47. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8:591-599.
48. Yajima T, Nishimura H, Ishimitsu R, et al. Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol. 2002;168:1198-1203.
49. Krug A, Rothenfusser S, Selinger S, et al. CpG-A ODN induce a monocyte-derived dendritic cell-like phenotype which preferentially activates CD8 T cells. J Immunol. 2003;170:3468-3477.
50. Erickson S, Sangfelt O, Castro J, et al. Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins. Cell Growth Differ. 1999;10:575-582.
51. Byrnes AA, Ma X, Cuomo P, et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol. 2001;31:2026-2034.
52. McRae BL, Beilfuss BA, van Seventer GA. IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells. J Immunol. 2000;164:23-28.
53. van Ojik H, Kruit W, Portielje J, et al. Phase 1/11 study with 7909 as adjuvant to vaccination with Mage-3 protein in patients with Mage-3 positive tumors [abstract]. Ann Oncol. 2003;13:157.